Diversified healthcare giant Johnson & Johnson (NYSE:JNJ) reported first-quarter profits on April 19 that beat analyst projections. The stock rallied a bit on the good news and pharmaceutical drug sales came in strong on new product launches. However, product recall costs continue to plague the company and growth trends have been anemic for several years now. Until J & J starts posting more consistent operating trends, a number of rivals look like better investment candidates.
TUTORIAL: Advanced Financial Statement Analysis

J&J's First-Quarter Recap
In the first quarter of 2011, total sales rose a modest 3.5% to $16.2 billion as organic growth of 1.8% combined with positive currency fluctuations of 1.7% to boost international and total company growth. The pharmaceutical division was the stand-out, with 7.5% growth to account for 37.5% of total sales as management stated sales of new drugs, including Stelara for the treatment of psoriasis and Simpon for the treatment of arthritis, posted strong performance. The medical device unit also posted decent growth as sales rose 3.3% to make up 39.8% of total sales on strong trends in glucose monitoring devices, disposable contact lenses and surgical care products.

The consumer unit made up the rest of the top line and saw sales fall 2.2% as product recalls, particularly in the McNeil Consumer Healthcare division, dented domestic sales by 13.8%. International sales continued to do well in the unit, rising 5.9%.

Reported net income fell 23.2% to $3.5 billion and earnings fell 22.8% to $1.25 per diluted share. The current quarter contained one-time litigation and recall charges, as did last year's first quarter. Backing out these non-recurring items, management estimated that earnings were $3.7 billion and $1.35 per diluted share, representing year-over-year growth in the low single digits.

Outlook for Johson & Johnson
Analysts currently project full-year sales growth of just over 4% and total sales of just over $64 billion. The company increased its earnings guidance and now expects full-year recurring profits between $4.90 and $5 per share for modest year-over-year growth of a couple of percent.

The strong pharma trends in Q1 are an encouraging sign for J&J and the company is staying active on the acquisition trail as well. It recently confirmed that management is talking with Swiss medical device firm Synthes about a potential $20 billion deal.

The Bottom Line
Despite its near-term woes, J&J remains extremely profitable. It didn't provide first-quarter balance sheet or cash flow data, but ended 2010 with close to $20 billion in net cash on the balance sheet and generated $14.5 billion in free cash flow, or approximately $5.21 per diluted share. (To learn more, see Free Cash Flow: Free, But Not Always Easy.)

J&J's forward earnings multiple continues to look appealingly low at about 12.4, but tangible signs of sustained sales growth and consistent profit expansion are still absent. As such, purer play rivals including Medtronic (NYSE:MDT), Teva Pharmaceuticals (Nasdaq:TEVA), Novartis (NYSE:NVS) and Stryker (NYSE:SYK) all look to have equally reasonable valuations given their projected growth rates over the longer haul.


Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  2. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  3. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  4. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  5. Investing

    Don't Freak Out Over Black Swans; Be Prepared

    Could 2016 be a big year for black swans? Who knows? Here's what black swans are, how they can devastate the unprepared, and how the prepared can emerge unscathed.
  6. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  7. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  8. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  9. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  10. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center